



(12) Translation of
European patent specification

(11) NO/EP 2252148 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/437 (2006.01)
A61P 1/00 (2006.01)
A61P 31/00 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2019.07.01

(80) Date of The European Patent Office Publication of the Granted Patent 2019.03.20

(86) European Application Nr. 09715020.5

(86) European Filing Date 2009.02.26

(87) The European Application's Publication Date 2010.11.24

(30) Priority 2008.02.26, US, 31679 P
2008.10.03, US, 102801 P

(84) Designated Contracting States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
Designated Extension States: AL; BA; RS

(73) Proprietor Salix Pharmaceuticals, Ltd., 1700 Perimeter Park Drive, Morrisville, NC 27560, USA

(72) Inventor FORBES, William, 1008 Heydon Court, Raleigh NC 27614, USA
JOHNSON, Lorin, 195-A Bryant Street, Palo Alto CA 94301, USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **METHODS FOR TREATING IRRITABLE BOWEL SYNDROME**

(56) References Cited:
WO-A2-2007/064964
US-A1- 2007 259 906
US-A1- 2005 272 754
WO-A2-2006/094737
STEFFEN ROBERT ET AL: "Therapy of travelers' diarrhea with rifaximin on various continents.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY MAY 2003, vol. 98, no. 5, May 2003 (2003-05), pages 1073-1078, XP002718619, ISSN: 0002-9270
E. SCARPELLINI ET AL: "High dosage rifaximin for the treatment of small intestinal bacterial overgrowth", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 25, no. 7, 1 April 2007 (2007-04-01), pages 781-786, XP55046220, ISSN: 0269-2813, DOI: 10.1111/j.1365-2036.2007.03259.x

LAURITANO ET AL.: 'Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth' THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. vol. 92, no. ISS.11, November 2007, pages 4180 - 4184, XP008140625

FRISSORA C L ET AL: "Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS 1 JUN 2007, vol. 25, no. 11, 1 June 2007 (2007-06-01), pages 1271-1281, XP002718617, ISSN: 0269-2813

DUPONT ET AL.: 'Rifaximin: A Nonabsorbed Antimicrobial in the Therapy of Travelers' Diarrhea' DIGESTION. vol. 59, no. ISS.6, November 1998, pages 708 - 714, XP008140624

BASS N M: "Review article: the current pharmacological therapies for hepatic encephalopathy", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 25, no. SUPPL 1, 1 February 2007 (2007-02-01), pages 23-31, XP002669397, ISSN: 0269-2813, DOI: 10.1111/J.1746-6342.2006.03218.X [retrieved on 2007-01-23]

Raleigh, N.C.: "Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study", www.drugs.com , September 2007 (2007-09), XP002718618, Retrieved from the Internet: URL:http://www.drugs.com/clinical_trials/rifaximin-demonstrates-statistically-significant-improvement-co-primary-endpoints-diarrhea-1851.html?printable=1 [retrieved on 2014-01-13]

'Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome' SALIX PHARMACEUTICALS, [Online] 06 December 2007, XP008140803 Retrieved from the Internet: <URL:http://clinicaltrials.gov/ct2/show/NCT_00269412>

SHAHARA ET AL.: 'A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence' AMERICAN JOURNAL OF GASTROENTEROLOGY. vol. 101, no. ISS.2, February 2006, pages 326 - 333, XP008140619

PIMENTEL ET AL.: 'The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome' ANNALS OF INTERNAL MEDICINE. vol. 145, no. ISS.8, 17 October 2006, pages 557 - 563, XP008140626

PIMENTEL MARK ET AL: "A 10-day course of rifaximin, a non-absorbable antibiotic, produces a durable improvement in all symptoms of irritable bowel syndrome: A double-blind randomized controlled study", GASTROENTEROLOGY, vol. 130, no. 4, Suppl. 2, April 2006 (2006-04), page A26, XP002718616, & DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 -24, 2006 ISSN: 0016-5085

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Rifaximin for anvendelse i behandling av diaré-assosiert irritabelt tarmsyndrom (Irritable Bowel Syndrom, dIBS) med en bestandig antibiotisk respons, hvori
1650 mg/dag rifaximin administreres fra 1 uke til omtrent 24 uker til et subjekt med behov for
5 samme;
hvori det er valgt subjekter som responderer på behandling etter å ha blitt behandlet i mellom
omtrent 1 og omtrent 24 uker; og
et responderende subjekt er fjernet fra behandling hvori det etter fjerning av behandling finnes en
vedvarende respons.
- 10 2. Rifaximin for anvendelse ifølge krav 1, hvori vedvarende respons omfatter kontinuerlig adekvat
lettelse av symptomer etter fjerning av behandling.
3. Rifaximin for anvendelse ifølge krav 1, hvori den vedvarende responsen omfatter fra mellom
omtrent 1 og omtrent 5 uker med adekvat lettelse av symptomer.
4. Rifaximin for anvendelse ifølge krav 3, hvori symptomer omfatter én eller flere av generelle IBS-
15 symptomer eller opphovning.
5. Rifaximin for anvendelse ifølge krav 1, hvori subjektet er et mannlig subjekt.
6. Rifaximin for anvendelse i akutt behandling av symptomatisk diaré-assosiert irritabelt
tarmsyndrom (Irritable Bowel Syndrom, dIBS), hvori 1650 mg/dag rifaximin administreres i 14 dager
til et subjekt med behov for samme, hvori fjerning av subjektet fra behandling etter de 14 dagene
20 resulterer i en vedvarende respons.
7. Rifaximin for anvendelse ifølge krav 1, hvori de lindrede symptomene omfatter én eller flere av
kontraksjoner, smerte, diaré, forstoppelse, klumpete avføring, våt avføring, hyppig produksjon av
avføring, abdominal smerte, abdominalt ubehag, nødvendighet eller tenesmus.
8. Rifaximin for anvendelse ifølge krav 1, hvori symptomene som er lindret omfatter ett eller flere
25 av symptomene med abdominal metthetsfølelse, opphovning, gass, eller oppblåsthet.
9. Rifaximin for anvendelse ifølge krav 1, hvori subjektet er et med en varighet av IBS på omtrent 5
til 10 år.
10. Rifaximin for anvendelse ifølge krav 1, hvori subjektet er ett som er eldre enn 65 år.
11. Rifaximin for anvendelse ifølge krav 1, hvori nevnte 1650 mg administreres som 550 mg tre
30 ganger per dag.